PD50-11 TRIMODAL THERAPY VERSUS RADICAL CYSTECTOMY FOR MUSCLE INVASIVE BLADDER CANCER - A MARKOV MICROSIMULATION MODEL

2020 ◽  
Vol 203 ◽  
pp. e1012
Author(s):  
Diana Magee* ◽  
Douglas Cheung ◽  
Amanda Hird ◽  
Srikala Sridhar ◽  
Charles Catton ◽  
...  
2021 ◽  
Vol 16 (4) ◽  
Author(s):  
Diana Magee ◽  
Douglas Cheung ◽  
Amanda Hird ◽  
Srikala S. Sridhar ◽  
Charles Catton ◽  
...  

Introduction: Radical cystectomy (RC) is the historic gold standard treatment for muscle-invasive bladder cancer (MIBC), but trimodal therapy (TMT) has emerged as a valid therapeutic option for selected patients. Given that prospective clinical trials have been difficult to perform in this area, our aim was to compare these two primary treatment strategies using decision analytic methods. Method: A two-dimensional Markov microsimulation model was constructed using TreeAge Pro to compare RC and TMT for patients with newly diagnosed MIBC. A comprehensive literature search was used to populate model probabilities and utilities. Our primary outcome was quality-adjusted life expectancy (QALE). Secondary outcomes included crude life expectancy (LE) and bladder cancer recurrences. The simulated patient for our model was an adult with MIBC (pT2-4 N0 M0) who was a candidate for either RC or TMT. Results: A total of 500 000 patients were simulated. TMT resulted in an estimated mean QALE of 7.48 vs. 7.41 for RC. However, the average LE for patients treated with TMT was lower compared with RC (10.20 vs. 10.74 years). A sensitivity analysis evaluating the impact of age showed that younger patients treated with RC had greater QALE and longer LE than those treated with TMT; inverse findings were observed for elderly patients. Overall, 39.4% of patients treated with TMT experienced a bladder recurrence. Conclusions: RC results in a longer LE compared to TMT (0.54 years), but with a lower QALE (-0.07 years). The preferred treatment strategy varied with patient age.


JAMA Surgery ◽  
2019 ◽  
Vol 154 (8) ◽  
pp. e191629 ◽  
Author(s):  
Stephen B. Williams ◽  
Yong Shan ◽  
Mohamed D. Ray-Zack ◽  
Hogan K. Hudgins ◽  
Usama Jazzar ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e16021-e16021
Author(s):  
Daniel Phillips ◽  
Tamer Dafashy ◽  
Yong Shan ◽  
Mohamed Danny Ray-Zack ◽  
Hogan K Hudgins ◽  
...  

e16021 Background: Earlier studies on the cost of muscle-invasive bladder cancer treatments lack granularity and are limited to 180 days. The objective of this study is to compare the one-year costs associated with trimodal therapy versus radical cystectomy, accounting for survival and intensity effects on total costs. Methods: This cohort study used the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Data analysis was performed from March 5, 2018 through December 4, 2018. A total of 2,963 patients aged 66-85 years diagnosed with clinical stage T2-4a muscle-invasive bladder cancer from January 1, 2002 through December 31, 2011. Total Medicare costs within one year of diagnosis following radical cystectomy versus trimodal therapy were compared using inverse probability of treatment-weighted (IPTW) propensity score models, which included a two-part estimator to account for intrinsic selection bias. Results: Median costs were significantly higher for trimodal therapy than radical cystectomy in 90 days ($83,754 vs. $68,692; median difference $11,805, 95% CI $7,745 to $15,864), 180 days ($187,162 vs. $109,078; median difference $62,370, 95% CI $55,581 to $69,160), and 365 days ($289,142 vs. $148,757; median difference $109,027, 95% CI $98,692 to $119,363), respectively. Outpatient care, radiology, medication expenses and pathology/laboratory costs contributed largely to the higher costs associated with trimodal therapy. On IPTW-adjusted analyses, patients undergoing trimodal therapy had $129,854 (95% CI $115,793-$145,299) higher costs compared with radical cystectomy one year after diagnosis. Conclusions: Compared to radical cystectomy, trimodal therapy was associated with higher costs among patients with muscle-invasive bladder cancer. Extrapolating cost figures resulted in nationwide excess spending of $444 million for trimodal therapy compared with radical cystectomy for patients diagnosed in 2017.


2021 ◽  
Vol 32 (4) ◽  
pp. 164
Author(s):  
StevenK Huang ◽  
Wen-Hsin Tseng ◽  
Chien-Liang Liu ◽  
Jinn-Rung Kuo ◽  
Shun-Hsing Hun ◽  
...  

JAMA Surgery ◽  
2018 ◽  
Vol 153 (10) ◽  
pp. 881 ◽  
Author(s):  
Stephen B. Williams ◽  
Yong Shan ◽  
Usama Jazzar ◽  
Hemalkumar B. Mehta ◽  
Jacques G. Baillargeon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document